← Back to Search

Inter-Atrial Shunt Device

Inter-Atrial Shunt Device for Heart Failure

N/A
Waitlist Available
Led By Sanjiv Shah, MD
Research Sponsored by Corvia Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 40 years old
Chronic symptomatic Heart Failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is testing a device to see if it can help reduce pressure in the left atrium for people with heart failure.

Who is the study for?
This trial is for adults over 40 with chronic heart failure who have a left ventricular ejection fraction of at least 40% and elevated left atrial pressure. They must be on stable heart failure medication, able to do some exercise but not too much (can walk between 50m and 600m in six minutes), and their kidneys must work well enough (estimated-GFR ≥25ml/min/1.73 m2). People with severe heart failure, recent heart attacks or surgeries, significant untreated artery blockages, serious valve disease, or recent strokes aren't eligible.Check my eligibility
What is being tested?
The study tests the IASD System II device designed by Corvia Medical to lower high pressure in the left atrium of the heart in patients with Heart Failure. It also uses Intracardiac Echo as part of the procedure to help doctors see inside the heart better during treatment.See study design
What are the potential side effects?
Potential side effects may include complications from placing the device like bleeding or infection, irregular heartbeat due to irritation inside the heart where the device sits, blood clots that could lead to stroke if they travel through holes made by the shunt device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 40 years old or older.
Select...
I have ongoing heart failure symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in supine exercise pulmonary capillary wedge pressure (PCWP)
Peri-procedural, and 1 month Major Adverse Cardiac, Cerebrovascular, and Renal Events (MACCRE)
Secondary outcome measures
Cardiovascular death
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ score)
Change in Quality Of Life Questionnaire (EQ-5D)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment with Inter-Atrial Shunt DeviceExperimental Treatment1 Intervention
Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
Group II: ControlPlacebo Group1 Intervention
Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.

Find a Location

Who is running the clinical trial?

Corvia MedicalLead Sponsor
7 Previous Clinical Trials
1,943 Total Patients Enrolled
7 Trials studying Heart Failure
1,943 Patients Enrolled for Heart Failure
Sanjiv Shah, MDPrincipal InvestigatorNorthwestern University
8 Previous Clinical Trials
2,795 Total Patients Enrolled
4 Trials studying Heart Failure
2,442 Patients Enrolled for Heart Failure

Media Library

IASD® System II (Inter-Atrial Shunt Device) Clinical Trial Eligibility Overview. Trial Name: NCT02600234 — N/A
Heart Failure Research Study Groups: Treatment with Inter-Atrial Shunt Device, Control
Heart Failure Clinical Trial 2023: IASD® System II Highlights & Side Effects. Trial Name: NCT02600234 — N/A
IASD® System II (Inter-Atrial Shunt Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02600234 — N/A
~5 spots leftby Jun 2025